This finding raises the question as to whether HRD-test-negative tumours containing a non-BRCA1/2 HRR pathogenic variant will respond to PARPi if they are in fact HRR proficient [53,54,55,56,57,58]. The gene discussed is BRCA1; the disease is neoplasm.